Potential New Weapon against Lou Gehrig's Disease

Mouse model suggests that a combination of therapies may stave off the onset of this neurodegenerative disorder















Share on Tumblr

neurons signal

STILL SIGNALING: Injecting a stress protein into mice with ALS appears to delay the onset of the disease by keeping motor neurons in the spinal cord humming. Image: © ISTOCKPHOTO/KIYOSHI TAKAHASE SEGUNDO

  • What a Plant Knows

    How does a Venus flytrap know when to snap shut? Can it actually feel an insect’s tiny, spindly legs? And how do cherry blossoms know when to bloom? Can they...

    Read More »

A protein that helps combat stress on cells caused by environmental influences like rising ambient temperatures appears to block the onset of amyotrophic lateral sclerosis (ALS), at least in a mouse model of the neurodegenerative illness.

Commonly known as Lou Gehrig's disease (after the famed New York Yankee slugger who succumbed to it in 1941 at age 37), ALS is a poorly understood, incurable disorder characterized by the degeneration of motor neurons (nerve cells that control voluntary motion). Signals from these cells to the muscles weaken in victims, resulting in atrophy, speech disruptions and, eventually, total loss of control over movement. About one in every 50,000 people in the U.S. is diagnosed with the debilitating condition annually; it typically strikes between the ages of 40 and 60 and leads to respiratory failure and death within five years of onset.

ALS ravages two distinct populations of motor neurons—one in the brain, the other in the spinal cord. The endings of the spinal cord cells interface with neighboring muscle cells, normally signaling muscles to contract or relax to create motion. But researchers at Wake Forest University Baptist Medical Center in Winston?Salem, N.C., found that ALS-affected neurons undergo a process known as "denervation" that severs the connection.

The scientists report in The Journal of Neuroscience, however, that they were able to preserve these neuromuscular links in mice genetically engineered to develop ALS by injecting heat protein 70 (Hsp70) into their backs, thus delaying the onset of the disease. This protein is secreted in large quantities by neurons in response to stressors. Hsp70 maintains proper nerve cell function by binding to the neurons and chaperoning proper protein folding inside. Previous models of ALS demonstrated that neurons sustain damage when stressed, because Hsp70 levels do not rise to corresponding levels.

"By keeping [muscle and nerve] cells talking to each other, you keep both cells healthy," says study co-author Carol Milligan, an assistant professor of neurobiology at W.F.U. Medical Center. "That keeps the motor neurons healthier longer." She notes that most existing and developing ALS therapies target cell bodies as opposed to the neuromuscular junction.

Genetic analyses have shown that 90 percent of ALS cases are caused by spontaneous mutations that are not inherited. In the 10 percent of inherited cases, a common mutation occurs in the gene superoxide dismutase 1 (SOD1), which is the gene that the Wake Forest team altered in its mouse model. Fifty days after the mice were born, one group was injected three times a week with Hsp70 and another received Riluzole, the only drug approved by the Food and Drug Administration to combat ALS.

The mice that received Riluzole lived, on average, one day longer than those that received no treatment. In contrast, those that received Hsp70 lived 10 days longer. At the neuromuscular juncture, where muscle and nerve cells meet, the researchers noted the Hsp70 mice had 20 percent more neurons in communication with muscle cells than the untreated control group.

"When we injected the protein, it tended to work more peripherally at the neuromuscular junction, and perhaps that is the difference," Milligan says. "We were assuming that it would go into the spinal cord and have an effect on the motor neuron cell body. … It suggests optimal treatment should be looking both at the periphery and at the spinal cord."

Milligan and her team now will attempt to uncover the mechanism by which the Hsp70 influx aids the so-called innervation of neurons and muscle cells. They will also explore therapeutic cocktails that include Hsp70 to target the neuromuscular juncture and at least one other component to attend nerve cell bodies.



1 Comments

Add Comment
View
  1. 1. luhng 04:16 PM 2/14/12

    once certain protiens are develpoed in the body the from birth depending if the mitochondrial dna or rna are specifically passed down from generation to generation then the attack can begin with the electric stimuli. Meaning that you can change the chemistry of the body through proper prolonged use higher ph water. various vitamines and the use of specific theropies tpo redevelope the brain and its chanles of thought.

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital

Latest from SA Blog Network

  SA Digital

Email this Article

Potential New Weapon against Lou Gehrig's Disease

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X